561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19

ABSTRACT: Abstract

Background

Remdesivir (RDV) has been shown to shorten recovery time and was well tolerated in patients with severe COVID-19. Here we report safety of RDV in patients with moderate COVID-19.

Methods

We conducted an open-label, phase 3 trial (NCT04252664) in hospitalized patients with confirmed SARS-CoV-2 infection, evidence of pulmonary infiltrates, and oxygen saturation >94% on room air. Patients were randomly assigned to receive RDV (5 or 10 days) or standard of care (SOC). RDV was dosed intravenously at 200 mg on day 1, 100 mg daily thereafter. Adverse events (AEs) and laboratory abnormalities were evaluated through the day 11 data cut; safety data through day 28 will be presented at the meeting.

Results

584 patients were randomized and treated (5d RDV

SUBMITTER: Criner G 

PROVIDER: S-EPMC7777368 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature